ARVINAS INC. - COMMON STOCK

Arvinas Announces Chief Financial Officer Transition

20 Feb 2024 16:05:04 By Nasdaq GlobeNewswire

Arvinas Announces First-in-Human Dosing of ARV-102, an Investigational PROTAC® Protein Degrader for Neurodegenerative Disease

20 Feb 2024 07:00:44 By Nasdaq GlobeNewswire

Arvinas and Pfizer’s Vepdegestrant (ARV-471) Receives FDA Fast Track Designation for the Treatment of Patients with ER+/HER2- Metastatic Breast Cancer

06 Feb 2024 06:45:00 By Nasdaq GlobeNewswire

Arvinas to Present at 6th Annual Guggenheim Biotechnology Conference

01 Feb 2024 16:30:20 By Nasdaq GlobeNewswire

Arvinas Appoints Jared Freedberg as General Counsel

16 Jan 2024 17:01:06 By Nasdaq GlobeNewswire

Arvinas to Host Conference Call and Webcast to Discuss Vepdegestrant (ARV-471) Data Presented at 2023 San Antonio Breast Cancer Symposium and Plans to Expand Vepdegestrant Development Program

05 Dec 2023 22:52:59 By Nasdaq GlobeNewswire

Arvinas and Pfizer Announce Interim Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®) and Plans to Expand Vepdegestrant Development Program

05 Dec 2023 13:33:42 By Nasdaq GlobeNewswire

Arvinas and Pfizer Announce Updated Vepdegestrant (ARV-471) Data to be Presented at the 2023 San Antonio Breast Cancer Symposium

28 Nov 2023 17:05:13 By Nasdaq GlobeNewswire

Arvinas Announces Oversubscribed $350 Million Private Placement

27 Nov 2023 07:00:10 By Nasdaq GlobeNewswire

Arvinas Reports Third Quarter 2023 Financial Results and Provides Corporate Update

07 Nov 2023 07:00:34 By Nasdaq GlobeNewswire

Arvinas to Participate in Upcoming Investor Conferences

02 Nov 2023 07:00:59 By Nasdaq GlobeNewswire

Potential of Arvinas’ PROTAC® AR Degraders Reinforced by 11.1 months rPFS with Bavdegalutamide and Updated Positive Interim Data from Second Generation ARV-766 in mCRPC

22 Oct 2023 07:00:58 By Nasdaq GlobeNewswire

Arvinas Gives Back to Local Greater New Haven Community in Second Annual Impact Day

18 Oct 2023 07:00:27 By Nasdaq GlobeNewswire

Arvinas Announces Upcoming Bavdegalutamide Poster Presentation at ESMO Congress 2023

15 Oct 2023 18:07:41 By Nasdaq GlobeNewswire

Arvinas and Pfizer Announce Upcoming Vepdegestrant (ARV-471) Poster Presentation at ESMO Congress 2023

15 Oct 2023 18:05:45 By Nasdaq GlobeNewswire

Arvinas to Participate in Upcoming Investor Conferences

01 Sep 2023 07:00:10 By Nasdaq GlobeNewswire

Arvinas Reports Second Quarter 2023 Financial Results and Provides Corporate Update

08 Aug 2023 07:00:18 By Nasdaq GlobeNewswire

Arvinas and Pfizer Awarded Innovation Passport Designation by the U.K. Innovative Licensing and Access Pathway Steering Group for Vepdegestrant, an Investigational PROTAC® ER degrader being developed in ER+/HER2- Breast Cancer

31 Jul 2023 16:30:14 By Nasdaq GlobeNewswire

Arvinas Announces Changes to its Board of Directors

15 Jun 2023 16:30:26 By Nasdaq GlobeNewswire

Arvinas Announces Interim Data from the ARV-766 Phase 1/2 Dose Escalation and Expansion Trial Showing Promising Signals of Efficacy in Late-line mCRPC, Including in Patients with AR L702H Mutations

08 Jun 2023 07:00:41 By Nasdaq GlobeNewswire